Home > Quotes > TRGT > Company News
TRGT

Targacept, Inc. News Headlines

$5.67
*  
0.13
  negative  
2.35%
Get TRGT Alerts
*Delayed - data as of May 21, 2013 11:47 ET 
Exchange: NASDAQ
Industry: Consumer Durables
Community Rating:
View:    TRGT Real Time
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored
Viewing
Filtered By
Ordered By

BIOL Does A Deal, BLRX's Lined Up Events, CBST On Fast Track, KERX On Watch
5/7/2013 10:36:00 PM - RTT News

Targacept To Present At Needham Conference; Webcast At 12:10 PM ET
4/30/2013 11:13:00 AM - RTT News

Targacept Completes Recruitment In Phase 2b Trial Of TC-1734
4/29/2013 12:47:00 PM - RTT News

Insiders Are Buying These 9 Environmentally Conscious Stocks
4/26/2013 5:42:00 AM - Seeking Alpha

5 Beaten Up Stocks That Insiders Think Can Rebound
4/13/2013 9:41:00 AM - Seeking Alpha

Insiders Are Buying These 4 Cash Rich Companies
4/7/2013 2:20:00 PM - Seeking Alpha

Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
3/15/2013 9:31:00 AM - Seeking Alpha

AstraZeneca/TRGT Restructure Deal - Analyst Blog
3/6/2013 7:15:01 PM - Zacks.com

Targacept Regains Rights to Compounds under Amended AstraZeneca Collaboration
3/5/2013 8:18:00 AM - Dow Jones Business News

Targacept, AstraZeneca Amend Collaboration - Quick Facts
3/5/2013 7:19:00 AM - RTT News

Targacept To Present At Cowen And Company Conference ; Webcast At 8:00 AM ET
3/5/2013 7:00:00 AM - RTT News

Revenues Rise at Incyte - Analyst Blog
2/15/2013 11:00:01 AM - Zacks.com

Data on Peregrine's Bavituximab - Analyst Blog
2/14/2013 5:00:01 PM - Zacks.com

Amgen Provides Long-Term Update - Analyst Blog
2/13/2013 5:46:04 PM - Zacks.com

SGEN Narrows Loss, Sales Rise - Analyst Blog
2/13/2013 10:58:01 AM - Zacks.com

Theravance Narrows Y/Y Loss - Analyst Blog
2/13/2013 10:41:01 AM - Zacks.com

UCB, Amgen Discontinue Study - Analyst Blog
2/12/2013 5:45:12 PM - Zacks.com

Priority FDA Review for Celgene Drug - Analyst Blog
2/12/2013 5:40:01 PM - Zacks.com

Loss at MannKind Wider than Expected - Analyst Blog
2/12/2013 12:45:35 PM - Zacks.com

Gilead Closes YM Biosciences Buyout - Analyst Blog
2/11/2013 7:13:01 PM - Zacks.com

Lannett Beats, Ups Guidance - Analyst Blog
2/11/2013 3:24:01 PM - Zacks.com

US Approval for Celgene's Pomalyst - Analyst Blog
2/11/2013 3:10:01 PM - Zacks.com

Loss Widens at Alnylam, Sales Fall - Analyst Blog
2/8/2013 1:00:01 PM - Zacks.com

Medivation's Xtandi Impresses - Analyst Blog
2/7/2013 5:30:01 PM - Zacks.com

Vivus Unveils Qsymia Study Results - Analyst Blog
2/7/2013 2:40:01 PM - Zacks.com